Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.
Neuzillet C, Marchais M, Vacher S, Hilmi M, Schnitzler A, Meseure D, Leclere R, Lecerf C, Dubot C, Jeannot E, Klijanienko J, Mariani O, Calugaru V, Hoffmann C, Lesnik M, Badois N, Borcoman E, Piaggio E, Kamal M, Le Tourneau C, Bieche I. Neuzillet C, et al. Among authors: dubot c. Sci Rep. 2021 Apr 12;11(1):7870. doi: 10.1038/s41598-021-86816-9. Sci Rep. 2021. PMID: 33846399 Free PMC article.
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé.
Pautier P, Genestie C, Gladieff L, Kurtz JE, Lortholary A, de La Motte Rouge T, Gaillard AL, Ducassou A, Dubot C, Rouleau E, Narducci F, Demontoy S, Hennequin C. Pautier P, et al. Among authors: dubot c. Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8. Bull Cancer. 2023. PMID: 37573038 French.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Ferron G, De Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, You B, Bouchaert P, Malaurie E, Gouy S, Kaminsky MC, Meunier J, Alexandre J, Berton D, Dohollou N, Dubot C, Floquet A, Favier L, Venat-Bouvet L, Fabbro M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Desauw C, Del Piano F, Leheurteur M, Bonichon-Lamichhane N, Rastkhah M, Follana P, Gantzer J, Ray-Coquard I, Pujade-Lauraine E. Ferron G, et al. Among authors: dubot c. Gynecol Oncol. 2023 Mar;170:186-194. doi: 10.1016/j.ygyno.2023.01.008. Epub 2023 Jan 25. Gynecol Oncol. 2023. PMID: 36706645 Clinical Trial.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators. Le Tourneau C, et al. Among authors: dubot c. Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3. Lancet Oncol. 2015. PMID: 26342236 Clinical Trial.
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.
Sablin MP, Dubot C, Klijanienko J, Vacher S, Ouafi L, Chemlali W, Caly M, Sastre-Garau X, Lappartient E, Mariani O, Rodriguez J, Jouffroy T, Girod A, Calugaru V, Hoffmann C, Lidereau R, Berger F, Kamal M, Bieche I, Le Tourneau C. Sablin MP, et al. Among authors: dubot c. Oncotarget. 2016 Jul 26;7(30):47418-47430. doi: 10.18632/oncotarget.10163. Oncotarget. 2016. PMID: 27329726 Free PMC article.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C. Belin L, et al. Among authors: dubot c. Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666. Ann Oncol. 2017. PMID: 27993804 Free article. Clinical Trial.
Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I. Dubot C, et al. Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11. Eur J Cancer. 2018. PMID: 29331751
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M. Basse C, et al. Among authors: dubot c. ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018. ESMO Open. 2018. PMID: 29636991 Free PMC article.
Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C, Kamal M, Vacher S, Chemlali W, Schnitzler A, Morel C, Dubot C, Jeannot E, Meseure D, Klijanienko J, Mariani O, Borcoman E, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Choussy O, Hoffmann C, Piaggio E, Bieche I, Le Tourneau C. Lecerf C, et al. Among authors: dubot c. Eur J Cancer. 2019 Nov;121:210-223. doi: 10.1016/j.ejca.2019.08.028. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593831
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C. Basse C, et al. Among authors: dubot c. JCO Precis Oncol. 2018 Oct 19;2:PO.18.00048. doi: 10.1200/PO.18.00048. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32914004 Free PMC article.
65 results